Physician profile
Febbie Phiri
NPI 1437818101
$30,921.44
in general payments reported to CMS, 2019-2025
44 companies · $11K in 2025
The $11K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $4,520 · 2023: $7,061 · 2024: $7,852 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $25K · Travel and Lodging: $1,274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $25,127.43 |
| Travel and Lodging | $1,274.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $5,796.82 | 2022-2025 | Minimed 780g, Inpen Smart Insulin Delivery System, Minimed 770g |
| Novo Nordisk INC | $3,157.13 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $2,382.77 | 2023-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $2,324.33 | 2022-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $1,995.14 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Mannkind Corporation | $1,442.81 | 2022-2025 | Afrezza, V-Go |
| Corcept Therapeutics | $1,424.11 | 2022-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $1,091.68 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,078.62 | 2022-2025 | Jardiance, Synjardy, Tradjenta |
| Amgen INC. | $1,059.97 | 2022-2025 | Tepezza, Repatha, Evenity |
| Astrazeneca Pharmaceuticals Lp | $1,034.63 | 2022-2024 | Farxiga, Lokelma |
| Novartis Pharmaceuticals Corporation | $943.42 | 2022-2025 | |
| Sequel Med Tech, LLC | $798.58 | 2025 | Twiist |
| Cequr Corporation | $740.60 | 2022-2025 | Cequr Simplicity |
| Radius Health, INC. | $715.02 | 2022-2025 | Tymlos |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascensia Diabetes Care US INC. | $711.31 | 2023-2025 | |
| Insulet Corporation | $469.26 | 2022-2025 | Omnipod |
| Madrigal Pharmaceuticals | $463.87 | 2025 | Rezdiffra |
| Beta Bionics, INC. | $415.67 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Tandem Diabetes Care, INC. | $350.91 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Kyowa Kirin, INC. | $315.53 | 2023-2025 | Crysvita |
| Bayer Healthcare Pharmaceuticals INC. | $282.56 | 2022-2025 | |
| Abbvie INC. | $281.84 | 2022-2025 | |
| Recordati_rare_diseases_inc. | $279.60 | 2022-2025 | Isturisa, Signifor Lar |
| Alexion Pharmaceuticals, INC. | $240.90 | 2023-2025 | Strensiq |
| Soleno Therapeutics, INC. | $162.67 | 2025 | Vykat Xr |
| Ipsen Biopharmaceuticals, INC | $156.93 | 2022-2024 | Iqirvo, Somatuline Depot |
| Esperion Therapeutics, INC. | $124.99 | 2022 | |
| Neurocrine Biosciences, INC. | $117.41 | 2024-2025 | |
| Antares Pharma, INC. | $76.50 | 2022-2023 | Tlando, Xyosted, Nocdurna |
| Averitas Pharma INC. | $58.12 | 2023-2025 | Qutenza |
| Merck Sharp & Dohme LLC | $56.66 | 2022 | |
| Tolmar, INC. | $55.56 | 2023-2024 | |
| Pfizer INC. | $44.19 | 2024-2025 | |
| Becton, Dickinson and Company | $43.07 | 2022 | |
| Eusa Pharma (US) LLC | $40.27 | 2022 | |
| Acerus Pharmaceuticals Corporation | $32.42 | 2022 | |
| Rhythm Pharmaceuticals, INC. | $32.30 | 2025 | Imcivree |
| Sanofi-Aventis U.S. LLC | $27.90 | 2025 | |
| Almatica Pharma LLC | $24.25 | 2024 | Teriparatide |
| Amarin Pharma, INC. | $21.61 | 2023 | |
| Amphastar Pharmaceuticals, INC. | $21.46 | 2025 | |
| Glaxosmithkline, LLC. | $20.84 | 2025 | Shingrix, Arexvy |
| Grt US Holding, INC. | $7.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Febbie Phiri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.